Mammalian RNAs can be edited by the conversion of adenosine to inosine, which is read as guanosine, but technological constraints have limited our view of the overall contribution of RNA editing ...

On October 16, a biotechnology company in Massachusetts in the U.S. named Wave Life Sciences made headlines for becoming the first company to treat a genetic condition by editing RNA at the ...

The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA ...

引言基因编辑的出现为生物学和医学研究带来了前所未有的突破，使得研究人员能够对生命的基本构建模块进行精确的操控。然而，传统的基因编辑技术，尽管在精度上有了很大提升，却仍然面临许多挑战，尤其是如何在不引入意外突变的情况下实现精准且多样化的基因改造。“引导 ...

Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD). Wave claims this is the first clinical ...

The only industry-led meeting showcasing the recent development of RNA editing mechanisms and dedicated to realizing the research and therapeutics opportunity of RNA editing as quickly as possible.

The researchers considered developing a gene therapy as an effective alternative to these regular eye injections. For the first time, they used the RNA editing tool CRISPR-Cas13 to suppress the ...

Retinitis pigmentosa (RP) is the most common hereditary degenerative eye disease that leads to progressive vision loss, primarily caused by retinal degeneration.

The company is generating significant interest from investors due to its dedication to RNA editing, a novel approach to ...